Trials / Not Yet Recruiting
Not Yet RecruitingNCT06035861
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
Investigating the Relationship Between Endothelial Cell Activation and Total Pulmonary Resistance in Pulmonary Artery Hypertension (PAH)
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Imperial College London · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether changes in endothelial cell dysfunction are associated with changes in total pulmonary resistance in patients with pulmonary arterial hypertension
Detailed description
Patients with PAH will be exposed to XBD173. Markers of endothelial cell dysfunction and activation will be measured in the plasma, and changes in total pulmonary resistance will be meausured with an implantable monitor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XBD173 | Participants will be treated with XBD173 90mg twice daily for 6 weeks |
Timeline
- Start date
- 2026-08-01
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
- First posted
- 2023-09-13
- Last updated
- 2026-03-25
Source: ClinicalTrials.gov record NCT06035861. Inclusion in this directory is not an endorsement.